Understand the source comparison
Best Peptides for Narcolepsy: Research Evidence Comparison
Cerebrolysin Neurotrophic peptide blend (BDNF-like, GDNF-like, NGF-like) supporting neuronal survival and synaptic plasticity May preserve residual orexin neurons (5–15% surviving cells) and stabilise hypothalamic circuits under chronic neurochemical deficit P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Neurotrophic peptide blend (BDNF-like, GDNF-like, NGF-like) supporting neuronal survival and synaptic plasticity
- May preserve residual orexin neurons (5–15% surviving cells) and stabilise hypothalamic circuits under chronic neurochemical deficit
- Preclinical models in neurodegeneration; no narcolepsy-specific trials
- Strongest neuroprotective profile for orexin-deficient type 1 narcolepsy. Mechanism aligns with preserving surviving neurons rather than replacing lost ones
- Dihexa
- HGF/c-Met pathway activator promoting synaptogenesis and dendritic spine formation
- Restores synaptic density in orexin-deficient arousal circuits; potent CNS penetration at low doses
- Animal cognition models; University of Washington research shows 7-order-of-magnitude greater potency than BDNF
- Best candidate for synaptic remodelling in sleep-wake circuits. Addresses circuit compensation rather than neuron replacement
- P21
- CNTF-derived STAT3 activator supporting neuronal survival and circuit stability
- Stabilises hypothalamic-thalamic-cortical arousal loops under chronic orexin deficiency
- Molecular Brain publication in aged animal models; cognitive and neuroplasticity marker improvements
- Mechanistically sound for circuit stabilisation. Less direct neuroprotection than Cerebrolysin but may support long-term adaptation
- Thymalin
- Thymic peptide immune modulator reducing T-cell-mediated inflammation
- Addresses autoimmune pathology of orexin neuron destruction in type 1 narcolepsy
- Autoimmune and neurodegenerative context studies; no narcolepsy-specific trials
- Only peptide targeting root autoimmune cause. Theoretical promise but weakest direct evidence for symptom improvement
- MK 677
- Ghrelin receptor agonist stimulating pulsatile GH release
- Restores disrupted GH secretion patterns and metabolic recovery during sleep
- JCEM clinical trials showing 60–120% GH increase and 40–90% IGF-1 elevation sustained over months
- Strongest metabolic normalisation candidate. Indirect support for neuroplasticity and sleep architecture rather than direct arousal effects
- Hexarelin
- Dual ghrelin receptor and CD36 agonist with GH-releasing and cardioprotective effects
- Metabolic optimisation plus cardiovascular protection in patients with autonomic instability
- Endocrinology research on cardiac function independent of GH; dual-receptor mechanism
- Best dual-purpose option for narcolepsy patients with cardiovascular comorbidities. Addresses metabolic and autonomic dysfunction simultaneously